Richard Finkel, MD
Pulmonary Disease · Denville, NJNPI 1124079520
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,325 of the $1,675 with a category attached, or 79.1%. It is spread thinly across 21 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $798 and has fallen 56.1% since, to $350 in 2025. That places this record below the midpoint for pulmonary disease clinicians in NJ, where the typical reported total is $2,135.
Across 90 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$391
- Jazz Pharmaceuticals Inc.$220
- Avadel CNS Pharmaceuticals, LLC$200
- AstraZeneca$192
- Boehringer Ingelheim$176
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$92
- plus $403 from 15 others
What the payments were for
- Consulting fees$35021%
- Food & beverage$1,32579%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 30 | $391 |
| Jazz Pharmaceuticals Inc. | 6 | $220 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $200 |
| AstraZeneca | 10 | $192 |
| Boehringer Ingelheim | 14 | $176 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 1 | $92 |
| Mylan Specialty L.p. | 5 | $83 |
| Philips North America LLC | 3 | $46 |
| Regeneron Healthcare Solutions, Inc. | 3 | $44 |
| Mallinckrodt Enterprises LLC | 3 | $40 |
| Grifols USA, LLC | 2 | $29 |
| Optinose US, Inc. | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Genentech USA, Inc. | 1 | $15 |
| Harmony Biosciences LLC | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Sanofi | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Merck | 1 | $13 |
| Kaleo, Inc. | 1 | $13 |
| Circassia Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,675 in reported general payments places this provider in the 45th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Denville
- Joseph HoffmanPark Ridge$1.1M
- Reynold PanettieriNew Brunswick$1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Richard MillerNewark$328K
- Jason ShatkinParamus$282K
- Anthony RickettiTrenton$225K
- Jeffrey MiskoffManasquan$176K
- Peter SacconeLinwood$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.